Key Takeaways Older diabetic patients on two GLP-1 drugs showed an increased risk of neovascular age-related macular degeneration in an observational cohort study.

Age-related macular degeneration (AMD) is a major cause of blindness, especially in older adults. A key feature of early AMD is the formation of drusen, clumps of debris made of lipids and ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing neovascular age-related macular degeneration (nAMD) in older patients with ...

Retinal prosthesis woven from tellurium nanowires partially restores vision in blind mice by Bob Yirka, Phys.org edited by Lisa Lock, reviewed by Robert Egan Editors' notes ...

While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in people with diabetes.

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for neovascular age-related macular degeneration in a large Canadian study.

Exploring the pathogenesis of age-related macular degeneration: A review of the interplay between retinal pigment epithelium dysfunction and the innate immune system.

Age-related macular degeneration begins with weakening of retinal pigment epithelium cells (RPEs), a layer of cells that support the retina's photoreceptors.

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. Character Biosciences has landed a $93 million series B to progress its precision ...

Biotechnology Macular degeneration-focused firm eyes the clinic after series B Character Biosciences raises $93 million to advance its peptide-based eye disease treatments by Asher Mullard ...

Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy fo ...

ENCELTO is an allogeneic encapsulated cell-based gene therapy indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).